相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。UniProt: the Universal Protein Knowledgebase in 2023
Alex Bateman et al.
NUCLEIC ACIDS RESEARCH (2023)
27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study
David L. Saltman et al.
CLINICAL LUNG CANCER (2023)
Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors
Mridula Krishnan et al.
JCO ONCOLOGY PRACTICE (2022)
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma
Zeynep B. Zengin et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
Harsha Ranganath et al.
BMC CANCER (2022)
Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients
Robert S. Seitz et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2022)
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Elaine Chang et al.
CLINICAL CANCER RESEARCH (2021)
Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
Sebastien Benzekry et al.
CANCERS (2021)
A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer
Toshiaki Iwase et al.
CANCERS (2021)
Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial
G. Bianchini et al.
ANNALS OF ONCOLOGY (2021)
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
Tracy L. Rose et al.
BRITISH JOURNAL OF CANCER (2021)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2021)
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study
Andrea Necchi et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies
Tyler J. Nielsen et al.
HELIYON (2021)
Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab
David L. Saltman et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors
Ali Raza Khaki et al.
CANCER (2020)
Bladder Cancer. Version 3.2020
Thomas W. Flaig et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection
Peter C. Black et al.
CUAJ-Canadian Urological Association Journal (2020)
Erdafitinib for the treatment of metastatic bladder cancer
Kamaneh Montazeri et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky et al.
LANCET (2020)
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
Adi Reches et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions
Juan Liu et al.
SCIENTIFIC REPORTS (2020)
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer
Li Wang et al.
EUROPEAN UROLOGY (2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Heidi Harjunpaa et al.
FRONTIERS IN IMMUNOLOGY (2019)
Exosomes in cancer development and clinical applications
Yu-Ling Tai et al.
CANCER SCIENCE (2018)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
Andrea Necchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
William C. Dougall et al.
IMMUNOLOGICAL REVIEWS (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status
Ho Won Kang et al.
ONCOLOGY LETTERS (2017)
Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients
Brian Z. Ring et al.
BMC CANCER (2016)
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Randy F. Sweis et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials
Kenneth F. Schulz et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2010)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)